NYSE:ZBHMedical Equipment
Is Zimmer Biomet’s Q4 Beat And 2026 Guidance Altering The Investment Case For ZBH?
Zimmer Biomet Holdings recently reported past fourth-quarter 2025 results with adjusted earnings per share of US$2.42 and net sales of US$2.24 billion, both ahead of analyst expectations and supported by growth across knees, hips, and S.E.T. products.
The company’s guidance for 2026, calling for revenue growth of 2.5% to 4.5% and adjusted earnings per share of US$8.30 to US$8.45, gives investors a clearer view of how its portfolio and recent innovations might shape financial performance over...